SLC5A2 and hydrops fetalis: Recent trials with SGLT2 inhibitors showed a beneficial effect of these drugs in HFpEF,5,20 thus providing relevant changes in the therapeutic approach to this condition to be applied in the near future.1,21 As regards the combined RAAS and neprilysin inhibition, sacubitril–valsartan failed to demonstrate a beneficial effect in HFpEF on the combined end point of CV mortality and total HF hospitalizations in the PARAGON-HF trial, although a trend towards a reduction in HF hospitalizations was observed.